From toxicity assessment to adaptive safety care: implementing comprehensive fast track safety evaluation for anticancer drug development ESMO Open Peptide Research Overview Mechanisms, Applications & Insights Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on Survival A pharmacovigilance datadriven approach to reveal high fatal adverse events following checkpoint immunotherapy PNAS Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab